FDA Staying The Course Under Ostroff; Hamburg’s Concerns Remain Focus
This article was originally published in The Tan Sheet
Executive Summary
Acting FDA Commissioner Ostroff says he does not envision new major priorities that would emerge in the short-term. The former FDA chief scientist is non-committal about submitting his name as a candidate for permanent commissioner.
You may also be interested in...
Hamburg, The Atypical Commissioner, Receives Atypically Fond Farewell
Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she leaves the agency in March with high drug approval numbers, initiatives to improve the OTC monograph and switch programs and increased enforcement in the supplement manufacturing arena.
Learning To Drive The ‘Chariot’: FDA Deputy Califf’s New Role
Renowned clinical trialist and cardiologist will become deputy commissioner for medical products and tobacco, a complicated and challenging position.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.